Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013477 | 0.82 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL30539494 | 0.82 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TAAR1ALDH1A1 | |
| SCHEMBL5012150 | 0.82 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL5013383 | 0.82 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TAAR1ALDH1A1 | |
| SCHEMBL11839087 | 0.82 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5013663 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TAAR1ALDH1A1 | |
| SCHEMBL11852666 | 0.80 | HTR2A (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27752629 | 0.80 | TAAR1 (0.44) | TAAR1NOS3NOS1NOS2P2RX3 | |
| SCHEMBL21385911 | 0.79 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL12250839 | 0.79 | P2RX3 (0.48) | SLC6A2SLC6A4SLC6A3TAAR1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305909-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305909-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | SLC6A2 2707/4885SLC6A4 3376/4885SLC6A3 2566/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | SLC6A2 2606/4885SLC6A4 2442/4885SLC6A3 1623/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | SLC6A2 2827/4885SLC6A4 2394/4885SLC6A3 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.